Repros Therapeutics : US76028H1005 / RPRX - NASDAQ

Ladenburg Thalmann - Repros Therapeutics "buy"

16:58 20.08.10
http://www.ariva.de/news/...erapeutics-buy-Ladenburg-Thalmann-3509779

Rating-Update:

New York (aktiencheck.de AG) - Die Analysten von Ladenburg Thalmann stufen die Aktie von Repros Therapeutics (Profil) von "neutral" auf "buy" hoch. Das Kursziel sehe man bei 1,50 USD. (20.08.2010/ac/a/u)

**************************************************

18.08.2010 12:31
http://www.finanznachrichten.de/...iii-protocols-for-androxal-004.htm
                    §
Repros Requests Type B Meeting with FDA to Discuss Phase III Protocols for Androxal®

Larry I. Lipshultz, MD Agrees to Serve as Lead Investigator for Phase III Program

Repros Therapeutics Inc. (NasdaqCM:RPRX) today announced that the Company has requested a Type B Meeting in order to review the Company's Phase III protocols for Androxal® in the treatment of secondary hypogonadism. Androxal is an oral drug that normalizes both testosterone and sperm levels.

Larry I. Lipshultz, MD, Baylor College of Medicine, Professor, Scott Department of Urology, Lester and Sue Smith Chair in Reproductive Medicine, and Past President, American Society for Reproductive Medicine has agreed to serve as Lead Investigator for the Company's Phase III program and will help Repros in preparing the pivotal protocols. The studies are being designed to show that only Androxal normalizes both testosterone and sperm concentrations as compared to topical testosterone or placebo. In a small pilot study previously conducted by Repros, only Androxal resulted in normalization of both testosterone and sperm counts in a majority of subjects. In this population of men that previously used a topical testosterone, no men on testosterone or placebo exhibited normal concentrations for both measures. Per FDA recommendation, benefit will be determined by "normalization of serum testosterone levels while preserving fertility."

Dr. Lipshultz commented, "In an era when increasingly more men are turning to testosterone replacement therapy for treatment of their low testosterone, it is important to many of these men to be able to maintain normal sperm production (spermatogenesis). Androxal has the potential to play an important role in helping to maintain normal sperm production in those men for whom testosterone replacement therapy is their best treatment and for whom the maintenance of normal spermatogenesis is equally as important."

**************************************************

13.08.2010 21:58
http://www.finanznachrichten.de/...-price-listing-requirement-004.htm

Nasdaq Grants Repros Extension until October 31, 2010 to Meet Minimum Bid Price Listing Requirement

Repros Therapeutics Inc. (NasdaqCM:RPRX) today announced that Nasdaq has granted the Company until October 31, 2010 to meet the minimum bid price requirement of the Nasdaq Capital Market. Listing Rule 5550(a)(2) requires the Company to maintain a minimum bid price of $1.00 for a minimum of ten consecutive trading days. At the Company's annual stockholders' meeting held on May 17, 2010, the stockholders approved a proposal to grant the Company's board of directors the authority to effect a reverse split of its common stock within one year of such annual meeting on a basis not to exceed one share of common stock for up to five shares of common stock outstanding, if necessary, in the sole discretion of the Company's board of directors, for purposes of maintaining its listing on the Nasdaq Capital Market.

In accordance with the decision of the Nasdaq Hearings Panel, Repros has to meet all of the continued listing requirements of the Nasdaq Capital Market by October 31, 2010, or its securities will, in all likelihood, be delisted from The Nasdaq Stock Market promptly following such date.

**************************************************

HOMEPAGE: www.reprosrx.com/  

wie es weitergeht nächste woche in usa.
und ob die anleger hier im forum wieder aktiv werden.

schöne weihnachten

max  

03.02.2011 21:39
http://www.finanznachrichten.de/...-common-stock-and-warrants-004.htm
                    §
Repros Therapeutics® Announces Pricing of Public Offering of Common Stock and Warrants

Repros Therapeutics Inc.® (NasdaqCM:RPRX) today announced the pricing of its public offering of 690,000 units, (including the exercise of the underwriter's overallotment option), consisting of 2,760,000 shares of its common stock, Series A Warrants to purchase 2,070,000 shares of common stock and Series B Warrants to purchase 1,690,500 shares of its common stock, at a price per unit of $17.15. Each unit consists of four shares of common stock, Series A Warrants exercisable for three shares of common stock at an exercise price of $0.01 per share and Series B Warrants exercisable for 2.45 shares of common stock at an exercise price of $2.49 per share. Gross proceeds to Repros, after the underwriting discount and before offering expenses, are expected to be approximately $11,000,000. Upon the closing of this offering, the Series A Warrants and Series B Warrants will be listed on the Nasdaq Capital Market under the symbols "RPRXW" and "RPRXZ," respectively. The offering is expected to close on or about February 8, 2011.

... (weiter siehe LINK)  

 

gings los ;-)  

An der Nasdag rauf um+ 140%!.Warum was sind die News?.Gruß Lars  

Eigentlich sollte heute eine Kursberuhigung stattfinden,ob es weiter nach oben in Richtung 4,-Dollar gehen wird muss abgewartet werden.  

 

heftiges Teil...  

An der Heimatbörse halten wir uns über die Marke von 3,- $US Dollar.Wäre klasse wenn wir diese bis zum Handelsende halten würden.Bis dato echt klasse entwickelt unter hohem Volumen.  

Hat nicht ganz gereicht mit den 3,- $ Dollar als Schlusskurs. Aber trotzdem auch heute mit sehr hohen Volumen wieder +20% Prozent an der Heimatbörse. Das zeigt das Interesse an dem Unternehmen bleibt weiter sehr hoch.Mal schauen ob es morgen an der Nasdag wieder up gehen wird ?.  

Am 5 Mai Q1 2016 sollen Zahlen kommen um 9 Uhr !.  

oder im Morningspike Breakout? Cup and Handle im 2-Tage-Chart.
Dürfte bei Breakout Kraft haben um den Widerstand bei ca. 3 USD zu knacken für ein
Doppeltop? Ziel 1 Morgen 3.20 USD evtl auch neue Hochs wegen Shortsqueeze.  

http://sleekmoney.com/...-28-00-consensus-pt-from-brokerages/1359450/  

hier auseinanderklaffen. Müsste man normalerweise mit einer kl. Posi rein :)  

 

- völlig überkauft  

0,40-0,45  

Gewinnmitnahmen - unter 0,70 dann SL Welle  

 

die Shorts haben das Ruder übernommen - da wird über 0,80 alles geshortet was geht. Nur noch eine Frage von ein paar Minuten das wir richtig fallen. Natürlich nur meine Meinung und keine Handelsempfehlung  

Ziel morgen im Tief 0,50$  

Alles mit Ansage  

 

https://de.marketscreener.com/kurs/aktie/...se-fur-2022-fes-40283250/